Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - October 2017

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Beclometasone / formoterol / glycopyrronium inhaler (Trimbow®) has been accepted for restricted use as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. The restriction limits use to patients with a forced expiratory volume in one second less than 50% predicted normal.

Opicapone (Ongentys®) has been rejected for use as an adjunctive therapy to preparations of levodopa / DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. The manufacturer did not make a submission to the SMC and therefore the product cannot be recommended.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - October 2017' on Email Share 'SMC Update - October 2017' on Delicious Share 'SMC Update - October 2017' on Digg Share 'SMC Update - October 2017' on Facebook Share 'SMC Update - October 2017' on reddit Share 'SMC Update - October 2017' on StumbleUpon Share 'SMC Update - October 2017' on Twitter

atomic-wealth

No Comments to “SMC Update - October 2017”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer